엔지켐생명과학

183490KOSDAQ기초 의약물질 제조업

45.5 / 100

Reference Date: 2026-04-13

Financial Score23.0 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure7.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Declined 11.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Enzychem Life Sciences focuses on global new drug development, API manufacturing, health functional foods, and bio-oil production. The company is advancing the development of EC-18, a treatment for chemotherapy-induced oral mucositis, and expanding into AI-driven drug discovery and DAC technology. Its API division exports over 40 products globally, while its health functional food segment offers immune-supporting products like 'LockFeed Immune'.

Number of Employees

116people

Average Salary

48.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 33.454.0Point

PBR

0.60Industry Average 2.037.0Point

Half of industry avg (excellent)

ROE

-12.05Industry Average -4.293.5Point

2.8x industry avg (excellent)

Debt Ratio

1.15Industry Average 6.618.0Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼5.3% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼0.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -9.7% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 990Won52-week high 1,69952-week low 968

1-month return1.0Point

1m -11.21% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

14 totalPositive 0Neutral 13Negative 1

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-08
Neutral주식등의대량보유상황보고서(일반)2026-04-07
Neutral주식등의대량보유상황보고서(약식)2026-04-06
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-04-01
Neutral정기주주총회결과2026-03-31